QL-007
Sponsors
Qilu Pharmaceutical Co., Ltd.
Conditions
Chronic Hepatitis b
Phase 2
An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy
NCT04157257
Start: 2019-07-26End: 2022-10-31Target: 60Updated: 2019-11-08
An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b
NCT04157699
Start: 2019-07-26End: 2022-10-31Target: 100Updated: 2019-11-12